Gelesis' proprietary superabsorbent hydrogel induced beneficial changes to the gut microbiota and expanded akkermansia, a bacterial species associated with gut health and weight loss, in new study

Boston--(business wire)--gelesis (nyse: gls), a consumer-focused biotherapeutics company and the maker of plenity®, released today a poster presentation at the world of microbiome annual meeting in vienna. the pre-clinical study showed administration of one of the company's proprietary superabsorbent hydrogels, gel-b, significantly shifted the composition of the microbiome to a profile correlated with better metabolic health, including improved weight and glucose control. adding gel-b to a high
GLS Ratings Summary
GLS Quant Ranking